Bio-Rad Laboratories, Inc. (Antibodies) products

Antibodies for bioanalysis and drug monitoring of adalimumab and biosimilars. Develop highly selective and sensitive PK and ADA assays for adalimumab (Humira) using our range of ready-made anti-idiotypic antibodies. Highly specific to adalimumab or the adalimumab-TNFα complex. Fully human surrogate positive control or calibrator. Sequence defined, well characterized reagents with secure supply. Recombinant production, stringent quality control for batch to batch consistency. Non-animal-derived antibodies, reducing the use of animals in science.

Recombinant Hepatitis B 320 Core Antigen 18kDa Ayw. Recombinant Hepatitis B core antigen is an E. coli-derived recombinant protein corresponding to full length Hepatitis B core antigen. Recombinant Hepatitis B core antigen is immunoreactive with sera from HBV-infected individuals.

Mouse anti Hepatitis B Core Antigen antibody, clone H3A4 (4H5) specifically recognizes Hepatitis B virus core antigen (HBcAg), the highly immunogenic 21kDa replicative form of the Hepatitis B virus (HBV), expressed by infected cells. Antibodies to HBcAg are produced by the host during and following an acute HBV infection and can be detected in chronic HBV carriers and patients recovered from HBV infection, usually persisting in the body for life.

Mouse anti Hepatitis B Core Antigen antibody, clone H3A4 (4H5) specifically recognizes Hepatitis B virus core antigen (HBcAg), the highly immunogenic 21kDa replicative form of the Hepatitis B virus (HBV), expressed by infected cells. Antibodies to HBcAg are produced by the host during and following an acute HBV infection and can be detected in chronic HBV carriers and patients recovered from HBV infection, usually persisting in the body for life.

The dengue virus (DENV), first isolated in 1943, is assigned to the family Flaviviridae, genus Flavivirus. It has four serotypes (DENV-1, DENV-2, DENV-3, and DENV-4) and transmission to humans occurs via the Aedes mosquito, mainly Aedes aegypti. Its global reach has mirrored the spread of Aedes aegypti in tropical and subtropical areas (Messina et al. 2014). It is suggested that 390 million dengue infections occur per year, of which 96 million develop symptoms (Bhatt et al. 2013).